Related Experiment Video
Updated: Jun 27, 2025
06:10
Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
Published on: May 9, 2025
195
T-Cell Engagers-The Structure and Functional Principle and Application in Hematological Malignancies
Paweł Cech1, Katarzyna Skórka1, Laura Dziki1
1Department of Experimental Hematooncology, Medical University of Lublin, 20-093 Lublin, Poland.
Cancers
|April 27, 2024
Summary
Bispecific antibodies (BsAbs), known as T-cell engagers (TCEs), are revolutionizing hematological cancer treatment by directing immune T-cells to target cancer cells. Ongoing research aims to overcome limitations and expand TCE therapy for better patient outcomes.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Cancer immunotherapy, particularly targeting hematological malignancies, has seen significant progress.
- Monoclonal antibody (mAb)-based therapies have improved patient prognosis but face limitations.
- Bispecific antibody (BsAb) formats, specifically T-cell engagers (TCEs), offer a novel therapeutic strategy.
Purpose of the Study:
- To summarize the technical basis of T-cell engager (TCE) technology.
- To review the application of TCEs in treating hematological malignancies.
- To discuss current challenges and future prospects of TCE-based therapies.
Main Methods:
- TCEs are bispecific antibodies targeting tumor antigens and CD3 on T-cells.
- This mechanism activates T-cells for direct tumor cell lysis.
- Blinatumomab, approved in 2014, exemplifies TCE therapy for acute lymphoblastic leukemia.
Main Results:
- Numerous TCEs have been developed for various hematological cancers, including acute myeloid leukemia, multiple myeloma, and lymphomas.
- As of November 2023, seven TCE therapies are clinically approved.
- TCEs have demonstrated efficacy in treating a range of hematological malignancies.
Conclusions:
- TCE technology represents a significant advancement in cancer immunotherapy for hematological malignancies.
- Despite current limitations, ongoing improvements and combination therapies offer hope for treating terminal diseases.
- Further research into TCE properties and applications is crucial for advancing cancer treatment.
Related Concept Videos
01:22T Cell Activation and Clonal Selection
714
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
714
01:27Tumor Immunotherapy
520
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
520
01:24T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
01:27Cytotoxic T Cells-mediated Immune Response
903
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
903
01:24B Cell Activation and Differentiation
1.7K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.7K
02:17The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K